We are international
Donate
• health professionals TEXT SIZE   
webcasts    back

Phase I evaluation of carfilzomib (PR-171) in hematological malignancies: Responses in multiple myeloma and Waldenstrom's macroglobulinemia at well-tolerated doses.
06.10.07
Keith Stewart, MD
Mayo Clinic
Scottsdale, Arizona, USA


 related articles